{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:36:15Z","timestamp":1760189775239,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Angiotensin Converting Enzyme Inhibitors (ACEI) are a common cause of Emergency Room presentation for angioedema. Although no treatment guidelines exist, C1 esterase inhibitor concentrate (C1-INH) is used on an off label basis for management of ACEI acquired angioedema (ACEI AAE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the efficacy of C1-INH in management of ACEI AAE at our local centers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine patients, from 3 academic sites, were identified through Allergy Service consultation data and records from Diagnostic Services Manitoba, Canada from 2010\u20132020. The majority of the patients (n\u2009=\u20098\/9) required endotracheal intubation prior to the initiation of C1-INH. Overall, approximately 56% of patients (n\u2009=\u20095\/9) had resolution of angioedema ranging between 12 and 17\u00a0h, with a median time of 13.5\u00a0h, and no recurrence after the administration of C1-INH concentrate. One patient had transient symptom resolution in 14\u00a0h, however, recurrence of angioedema required re-intubation. The remainder of patients (n\u2009=\u20094\/9), had resolution of angioedema between 22 and 72\u00a0h, with a median time of 33.75\u00a0h.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings demonstrate continued ambivalence of the efficacy and role of C1-INH concentrate in the treatment of ACEI AAE, secondary to multiple uncontrolled confounding factors. Further research into characterizing a subgroup of intubated patients in our study that responded to C1-INH concentrate needs to be completed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-021-00521-w","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T17:53:41Z","timestamp":1613584421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-1589","authenticated-orcid":false,"given":"Uliana","family":"Kovaltchouk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystyna","family":"Kalicinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"1","key":"521_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s40521-019-0203-y","volume":"6","author":"I Terreehorst","year":"2019","unstructured":"Terreehorst I, Reitsma S, Cohn DM. Current Treatment of Angioedema Induced by ACE Inhibitors. Curr Treat Options Allergy. 2019;6(1):18\u201326.","journal-title":"Curr Treat Options Allergy"},{"issue":"3","key":"521_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2340\/00015555-1760","volume":"94","author":"ER Rasmussen","year":"2014","unstructured":"Rasmussen ER, Mey K, Bygum A. Angiotensin-converting enzyme inhibitor-induced angioedema\u2014a dangerous new epidemic. Acta Derm Venereol. 2014;94(3):260\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"521_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103\u201311.","journal-title":"Am J Hypertens."},{"key":"521_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106081","author":"V Montinaro","year":"2020","unstructured":"Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. Int Immunopharmacol. 2020. https:\/\/doi.org\/10.1016\/j.intimp.2019.106081.","journal-title":"Int Immunopharmacol"},{"issue":"9117","key":"521_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amustutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351(9117):1693\u20137.","journal-title":"Lancet"},{"issue":"1","key":"521_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","volume":"51","author":"JB Byrd","year":"2008","unstructured":"Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51(1):141\u20137.","journal-title":"Hypertension"},{"issue":"7","key":"521_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","volume":"20","author":"WJ Kostis","year":"2018","unstructured":"Kostis WJ, Shetty M, Chowdury YS, Kostis JB. ACE Inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"521_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000368404","volume":"165","author":"TJ Craig","year":"2014","unstructured":"Craig TJ, Bernstein JA, Farkas H, Bouillet L, Boccon-Gibod I. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol. 2014;165(2):119\u201327.","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"521_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaci.2010.06.022","volume":"126","author":"P Lieberman","year":"2010","unstructured":"Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, Bernstein JA, Burks AW, Feldweg AM, Fink JN, Greenberger PA, Golden DB, James JM, Kemp SF, Ledford DK, Lieberman P, Sheffer AL, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang D, Nicklas RA, Oppenheimer J, Protnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477\u201380.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"521_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/all.13384","volume":"73","author":"M Maurer","year":"2018","unstructured":"Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, Bowen T, Balle Boysen H, Farkas H, Grumach AS, Hide M, Katelaris C, Lockey R, Longhurst H, Lumry WR, Martinez-Saguer I, Moldovan D, Nast A, Pawankar R, Potter P, Riedl M, Ritchie B, Rosenwasser L, Sanchez-Borges M, Zhi Y, Zuraw B, Craig T. The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2017 revision and update. Allergy. 2018;73(8):1575\u201396.","journal-title":"Allergy"},{"issue":"6","key":"521_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/lary.25113","volume":"125","author":"J Greve","year":"2015","unstructured":"Greve J, Bas M, Hoffmann TK, Schuler PJ, Weller P, Kojda G, Strassen U. Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2015;125(6):198\u2013202.","journal-title":"Laryngoscope"},{"issue":"4","key":"521_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","volume":"100","author":"A Banerji","year":"2008","unstructured":"Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100(4):327.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"521_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1399-6576.2005.00819.x","volume":"50","author":"EW Nielsen","year":"2006","unstructured":"Nielsen EW, Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand. 2006;50(1):120\u20132.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"521_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1177\/0897190016677427","volume":"30","author":"M Leibfried","year":"2017","unstructured":"Leibfried M, Kovary A. C1 esterase inhibitor (Berinert) for ACE inhibitor-induced angioedema: two case reports. J Pharm Pract. 2017;30(6):668\u201371.","journal-title":"J Pharm Pract"},{"issue":"5","key":"521_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jemermed.2017.05.037","volume":"53","author":"HM Riha","year":"2017","unstructured":"Riha HM, Summers BB, Rivera JV, Van Berkel MA. Novel therapies for angiotensin-converting enzyme inhibitor-induced angioedema: a systematic review of current evidence. J Emerg Med. 2017;53(5):662\u201379.","journal-title":"J Emerg Med"},{"issue":"9","key":"521_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/00128071-200203090-00002","volume":"3","author":"M Sanchez-Borges","year":"2002","unstructured":"Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol. 2002;3(9):599\u2013607.","journal-title":"Am J Clin Dermatol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00521-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13223-021-00521-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00521-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T17:59:18Z","timestamp":1613584758000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00521-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00521-w","relation":{},"ISSN":["1710-1492"],"issn-type":[{"type":"electronic","value":"1710-1492"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was received from the University of Manitoba health research ethics board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The University of Manitoba health research ethics board has provided us with consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests from either of the authors listed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}